- Novartis gets rights to Arakis and Vectura's AD237
- Arakis, Vectura develop inhalable therapeutic
- Amgen and Biovitrum sign license agreements
- Pharmacia co-promotes Celltech's CDP870; terminated
- Vectura completes £20mm IPO
- Boehringer Ingelheim, Pfizer to co-promote Spiriva
- GSK signs broad collaboration with Theravance
- GSK, Theravance develop respiratory drug candidates
- Altana, Pharmacia develop and market roflumilast; deal ends
- Arakis closes £29mm third round
- SkyePharma and Novartis develop asthma and COPD treatment
Ask The Analyst
Ask the Analyst is free for subscribers. Submit your question and one of our analysts will be in touch.
Your question has been successfully sent to the email address below and we will get back as soon as possible. email@example.com.
All fields are required.
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.